Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Must not be pregnant or breastfeeding and agree to use birth control;~* Completion of a negative colonoscopy as per American Gastroenterology Association (AGA) criteria and no clinically-significant laboratory or physical examination findings;~* Meets protocol-defined criteria for IBS-C, including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria;~* Demonstrates English fluency and has access to a touch-tone telephone.~Exclusion Criteria:~* Recent history of mushy or watery stools;~* Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study;~* Clinically-significant alarm symptoms;~* Secondary causes of constipation or evacuation disorders;~* Surgery to the gastrointestinal tract;~* Usage of prohibited medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 72 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 145 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 290 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 579 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- Matching Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).